Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$2.60
+7.4%
$4.63
$2.09
▼
$7.65
$130.87M1.52.02 million shs2.54 million shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
0.00%-41.97%-45.37%-59.26%-45.62%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$2.60
+7.4%
$4.63
$2.09
▼
$7.65
$130.87M1.52.02 million shs2.54 million shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
0.00%-41.97%-45.37%-59.26%-45.62%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
2.67
Moderate Buy$21.00707.69% Upside

Current Analyst Ratings Breakdown

Latest ABEO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/10/2026
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
DowngradeSell (D) ➝ Sell (D-)
9/25/2026
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
Reiterated RatingBuy
9/25/2026
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
Reiterated RatingBuy
9/18/2026
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
Boost Price TargetOverweight$28.00 ➝ $30.00
9/17/2026
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
Initiated CoverageBuy$17.00
9/17/2026
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
Initiated CoverageBuy$17.00
8/17/2026
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
DowngradeSell (D+) ➝ Sell (D)
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$5.82M25.53N/AN/A$2.20 per share1.18
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$71.18M-$1.07N/AN/AN/A-160.30%-44.82%-32.51%N/A

Latest ABEO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q3 2026
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
-$0.1743-$0.08+$0.0943-$0.08$14.82 million$13.49 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
N/A
5.69
6.40

Institutional Ownership

CompanyInstitutional Ownership
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
80.56%

Insider Ownership

CompanyInsider Ownership
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
7.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
22657.15 million53.09 millionOptionable

Recent News About These Companies

HC Wainwright Has Positive Forecast for ABEO FY2026 Earnings
Abeona Therapeutics (NASDAQ:ABEO) Stock Bumped Up to Hold by Wall Street Zen
Abeona Therapeutics acquires ABO-801 from Ellodi
Abeona Therapeutics (ABEO) Q3 2026 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abeona Therapeutics stock logo

Abeona Therapeutics NASDAQ:ABEO

$2.60 +0.18 (+7.44%)
Closing price 04:00 PM Eastern
Extended Trading
$2.61 +0.01 (+0.38%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.